Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals

The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes

Pfizer reports breakthrough in advanced prostate cancer with TALZENNA Plus XTANDI

The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial

Pfizer drug candidate shows strong results in tough breast cancer study

The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged

EU clears AstraZeneca’s Imfinzi combo for early gastric & GEJ cancers

AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible

Allergan Aesthetics unveils ‘Skin Quality Index’ to close gap between patients & doctors

The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health

Eli Lilly’s EBGLYSS shows breakthrough results in children with severe eczema

The company announced positive topline data from the Phase 3 ADorable-1 trial

Samsung Biologics, Eli Lilly team up to launch major biotech hub in Korea

The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms

Virta Health shows nutrition therapy may extend life in advanced pancreatic cancer

The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months

Cbio launches first-in-human trial for groundbreaking cervical cancer therapy